As part of the Inflation Reduction Act, price negotiations with manufacturers will begin this year, with reduced prices ...

The company revealed plans to increase the usage of AI in pharma at JP Morgan’s healthcare conference in San Francisco. Over the past two years, the life sciences industry has seemingly fully embraced ...

Organizations including Gilead, Eli Lilly, and AbbVie announced a number of deals addressing inflammatory diseases, multiple myeloma, and other disease areas. With the start of the annual JP Morgan ...

The digital transformation of the pharmaceutical industry continues to provide innovative ways to improve the clinical research process. With the growing importance of strategies like real-time data ...

The Healthcare Businesswomen’s Association (HBA) announced that it has named Reshema Kemps-Polanco, executive vice president and chief commercial officer at Novartis US, as its Woman of the Year. 1 ...

John Hood, CEO, Endeavor BioMedicines discusses partnering with advocacy groups to increase awareness of clinical trials for idiopathic pulmonary fibrosis. PE: Are there any ongoing collaborations ...

Teva Pharmaceuticals announced two strategic collaborations to expand its biosimilar portfolio and enhance access to high-cost biologics across key markets. The first deal, which is with Formycon AG ...

Moderna provided updates on key elements of its pipeline, including a next-generation COVID-19 vaccine, an RSV vaccine, a new seasonal flu, and a combination seasonal flu/COVID vaccine. Moderna ...

Biohaven presented positive news regarding its portfolio during its presentation at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13. In a press release, the company’s CEO Vlad ...

The campaign will include patient stories, education resources, and is being held in partnership with the Glaucoma Research Foundation. Bausch + Lomb announced the launch of the second annual Faces of ...

Acceptance of the Biologics License Application for subcutaneous Leqembi is based on results from the Clarity AD open-label extension and modeling of observed data in patients with Alzheimer disease.

Novo Holdings announced an investment in a $200M Series A launch financing for Swiss company Windward Bio. 1 The clinical stage drug development company is developing treatments for immunological ...